Literature DB >> 23890842

Intrahepatic cholangiocarcinoma: management options and emerging therapies.

Rebecca M Dodson1, Matthew J Weiss, David Cosgrove, Joseph M Herman, Ihab Kamel, Robert Anders, Jean-Francois H Geschwind, Timothy M Pawlik.   

Abstract

Entities:  

Keywords:  AJCC; American Joint Committee on Cancer; EGFR; HBV; HCC; HCV; IBD; ICC; LN; PSC; VEGF; epidermal growth factor receptor; hepatitis B virus; hepatitis C virus; hepatocellular carcinoma; inflammatory bowel disease; intrahepatic cholangiocarcinoma; lymph node; primary sclerosing cholangitits; vascular endothelial growth factor

Mesh：

Year:  2013        PMID： 23890842     DOI： 10.1016/j.jamcollsurg.2013.05.021

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN： 1072-7515            Impact factor:   6.113


× No keyword cloud information.
  63 in total

1.  Focal liver lesions suspected of being cholangiocarcinomas.

Authors:  Nicola Zanini; Elio Jovine; Giovanni Landolfo
Journal:  Am J Gastroenterol       Date:  2015-04       Impact factor: 10.864

Review 2.  Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects.

Authors:  Lynn Jeanette Savic; Julius Chapiro; Jean-François H Geschwind
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

3.  Readmission After Liver Resection for Intrahepatic Cholangiocarcinoma: a Multi-Institutional Analysis.

Authors:  Gaya Spolverato; Hadia Maqsood; Alessandro Vitale; Sorin Alexandrescu; Hugo P Marques; Luca Aldrighetti; T Clark Gamblin; Carlo Pulitano; Todd W Bauer; Feng Shen; George Poultsides; Shishir Maithel; J Wallis Marsh; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-04-23       Impact factor: 3.452

Review 4.  Transcatheter embolization therapy in liver cancer: an update of clinical evidences.

Authors:  Yì-Xiáng J Wáng; Thierry De Baere; Jean-Marc Idée; Sébastien Ballet
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

5.  Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium.

Authors:  Xu-Feng Zhang; Eliza W Beal; Jeffery Chakedis; Qinyu Chen; Yi Lv; Cecilia G Ethun; Ahmed Salem; Sharon M Weber; Thuy Tran; George Poultsides; Andre Y Son; Ioannis Hatzaras; Linda Jin; Ryan C Fields; Stefan Buettner; Charles Scoggins; Robert C G Martin; Chelsea A Isom; Kamron Idrees; Harveshp D Mogal; Perry Shen; Shishir K Maithel; Carl R Schmidt; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

6.  Comparison of perioperative and oncologic outcomes between open and laparoscopic liver resection for intrahepatic cholangiocarcinoma.

Authors:  Woohyung Lee; Ji-Ho Park; Ju-Yeon Kim; Seung-Jin Kwag; Taejin Park; Sang-Ho Jeong; Young-Tae Ju; Eun-Jung Jung; Young-Joon Lee; Soon-Chan Hong; Sang-Kyung Choi; Chi-Young Jeong
Journal:  Surg Endosc       Date:  2016-02-22       Impact factor: 4.584

7.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

8.  A simple and effective prognostic staging system based on clinicopathologic features of intrahepatic cholangiocarcinoma.

Authors:  Huabang Zhou; Xiaolan Jiang; Qiaomei Li; Jingyi Hu; Zhengrong Zhong; Hao Wang; Hui Wang; Bing Yang; Heping Hu
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

Review 9.  The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics.

Authors:  Yuji Morine; Mitsuo Shimada
Journal:  J Gastroenterol       Date:  2015-04-02       Impact factor: 7.527

Review 10.  Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis.

Authors:  Gábor Lendvai; Tímea Szekerczés; Idikó Illyés; Réka Dóra; Endre Kontsek; Alíz Gógl; András Kiss; Klára Werling; Ilona Kovalszky; Zsuzsa Schaff; Katalin Borka
Journal:  Pathol Oncol Res       Date:  2018-11-17       Impact factor: 3.201
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.